Safety Parameters and Risk Categories Used for Psychotropic Drugs in Pregnancy and Lactation

  • Yusuf Cem Kaplan
  • Hilal Erol-Coskun


Pharmacotherapy is frequently required for pregnant and breastfeeding women with psychiatric illness. This chapter aims to review the basic principles for assessing medication use during pregnancy and lactation in order to help clinical decision-making. The concepts are exemplified by psychotropic drugs, in case the information is available. An update on recent changes in the FDA pregnancy risk categories is also provided.


Psychotropic drugs Safety Pregnancy Teratology Risk assessment Breastfeeding Lactation 


  1. 1.
    Källén B. Drugs in pregnancy - the dilemma of labeling. Drug Inf J. 1999;33:1135–43.CrossRefGoogle Scholar
  2. 2.
    Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23(3):245–53.CrossRefGoogle Scholar
  3. 3.
    Dunlop AL, Jack BW, Bottalico JN, Lu MC, James A, Shellhaas CS, Hallstrom LH, Solomon BD, Feero WG, Menard MK, Prasad MR. The clinical content of preconception care: women with chronic medical conditions. Am J Obstet Gynecol. 2008;199(6 Suppl 2):S310–27.CrossRefGoogle Scholar
  4. 4.
    Chatterjee S, Kotelchuck M, Sambamoorthi U. Prevalence of chronic illness in pregnancy, access to care, and health care costs: implications for interconception care. Womens Health Issues. 2008;18(6 Suppl):S107–16.CrossRefGoogle Scholar
  5. 5.
    Kersten I, Lange AE, Haas JP, Fusch C, Lode H, Hoffmann W, Thyrian JR. Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study. BMC Pregnancy Childbirth. 2014;14:75.CrossRefGoogle Scholar
  6. 6.
    Feibus KB. FDA’s proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use. J Med Toxicol. 2008;4:284–8.CrossRefGoogle Scholar
  7. 7.
    Frederiksen MC. The new FDA pregnancy labeling requirements for drugs. J Midwifery Womens Health. 2011;56:303–7.CrossRefGoogle Scholar
  8. 8.
    Sahin L, Nallani SC, Tassinari MS. Medication use in pregnancy and the pregnancy and lactation labeling rule. Clin Pharmacol Ther. 2016;100(1):23–5.CrossRefGoogle Scholar
  9. 9.
    Brent RL. Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents). Pediatrics. 2004a;113(4 Suppl):984–95.PubMedGoogle Scholar
  10. 10.
    Grigoriadis S, Vonderporten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932.CrossRefGoogle Scholar
  11. 11.
    Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs. 2008;22:325–234.CrossRefGoogle Scholar
  12. 12.
    Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, Nakane Y, Ogawa Y, Avanzini G, Fumarola C, Granata T, Molteni F, Pardi G, Minotti L, Canger R, Dansky L, Oguni M, Lopes-Cendas I, Sherwin A, Andermann F, Seni MH, Okada M, Teranishi T. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 1999;33(2-3):145–58.CrossRefGoogle Scholar
  13. 13.
    Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F, EURAP Study Group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.CrossRefGoogle Scholar
  14. 14.
    Bromley RL, Mawer G, Love J, Kelly J, Purdy L, McEwan L, Briggs M, Clayton-Smith J, Shi X, Baker GA. Liverpool and Manchester Neurodevelopment Group (LMNDG): Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010;51:2058–65.CrossRefGoogle Scholar
  15. 15.
    Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW. NEAD Study Group: Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360:1597–605.CrossRefGoogle Scholar
  16. 16.
    Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW Jr, Lott IT, Richard JM, Sun SC. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837–41.CrossRefGoogle Scholar
  17. 17.
    Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream. Lancet. 1992;339(8794):687.CrossRefGoogle Scholar
  18. 18.
    Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993;341(8856):1352–3.CrossRefGoogle Scholar
  19. 19.
    Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341(8854):1181–2.CrossRefGoogle Scholar
  20. 20.
    Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136(2):117–21.CrossRefGoogle Scholar
  21. 21.
    Panchaud A, Csajka C, Merlob P, Schaefer C, Berlin M, De Santis M, Vial T, Ieri A, Malm H, Eleftheriou G, Stahl B, Rousso P, Winterfeld U, Rothuizen LE, Buclin T. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol. 2012;52(12):1844–51.CrossRefGoogle Scholar
  22. 22.
    Shapiro L, Pastuszak A, Curto G, Karen G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet. 1997;350(9085):1143–4.CrossRefGoogle Scholar
  23. 23.
    Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G. Pregnancy outcomes following first trimester exposure to topical retinoids: a systematic review and meta-analysis. Br J Dermatol. 2015b;173(5):1132–41.CrossRefGoogle Scholar
  24. 24.
    Jensen BK, McGann LA, Kachevsky V, Franz TJ. The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol. 1991;24:425–8.CrossRefGoogle Scholar
  25. 25.
    Lehman PA, Slattery JT, Franz TJ. Percutaneous absorption of retinoids: influence of vehicle, light exposure, and dose. J Invest Dermatol. 1988;91:56–61.CrossRefGoogle Scholar
  26. 26.
    Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3(7):pii: e003062.CrossRefGoogle Scholar
  27. 27.
    Vajda FJ. The Australian pregnancy register of antiepileptic drugs: 10 years of progress. J Clin Neurosci. 2010;17:1485–8.CrossRefGoogle Scholar
  28. 28.
    Vajda FJ, Hitchcock AA, Graham J, O’Brien TJ, Lander CM, Eadie MJ. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia. 2010;51:805–10.CrossRefGoogle Scholar
  29. 29.
    Vajda FJ, O’Brien TJ, Lander CM, Graham J, Eadie MJ. Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia. 2016;57(7):1048–52.CrossRefGoogle Scholar
  30. 30.
    Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157(3):175–82.CrossRefGoogle Scholar
  31. 31.
    Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol. 2002;100(3):465–73.PubMedGoogle Scholar
  32. 32.
    Brent RL. Environmental causes of human congenital malformations: the pediatrician’s role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics. 2004b;113(4 Suppl):957–68.PubMedGoogle Scholar
  33. 33.
    Guittina P, Eléfant E, Saint-Salvi B. Hierarchization of animal teratology findings for improving the human risk evaluation of drugs. Reprod Toxicol. 2000;14:369–75.CrossRefGoogle Scholar
  34. 34.
    Shepard TH. Proof of human teratogenicity. Teratology. 1994;50:97–8.CrossRefGoogle Scholar
  35. 35.
    Carey JC, Martinez L, Balken E, Leen-Mitchell M, Robertson J. Determination of human teratogenicity by the astute clinician method: review of illustrative agents and a proposal of guidelines. Birth Defects Res A Clin Mol Teratol. 2009;85(1):63–8.CrossRefGoogle Scholar
  36. 36.
    Fourie DT, Hay IT. Warfarin as a possible teratogen. S Afr Med J. 1975;49(50):2081–3.PubMedGoogle Scholar
  37. 37.
    Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet. 1976;2(7991):914–5.CrossRefGoogle Scholar
  38. 38.
    Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence: a report of 7 cases including 6 clear-cell carcinomas. Cancer. 1970;25:745–57.CrossRefGoogle Scholar
  39. 39.
    Rosa FW. Teratogenicity of isotretinoin. Lancet. 1983;2:513.CrossRefGoogle Scholar
  40. 40.
    Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J. 1992;11(12):1062–4.CrossRefGoogle Scholar
  41. 41.
    Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley J. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22(2):336–40.CrossRefGoogle Scholar
  42. 42.
    Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol. 2004;103(5 Pt 2):1091–4.CrossRefGoogle Scholar
  43. 43.
    Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82(12):1698–7102.CrossRefGoogle Scholar
  44. 44.
    Song F, Hooper L, Loke YK. Publication bias: what is it? How do we measure it? How do we avoid it. Open Access J Clin Trials. 2013;5(1):51–81.Google Scholar
  45. 45.
    Leen-Mitchell M, Martinez L, Gallegos S, Robertson J, Carey JC. Mini-review: history of organized teratology information services in North America. Teratology. 2000;61:314–7.CrossRefGoogle Scholar
  46. 46.
    Schaefer C. Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services. Congenit Anom (Kyoto). 2011;51:6–11.CrossRefGoogle Scholar
  47. 47.
    Irl C, Hasford J. Assessing the safety of drugs in pregnancy: the role of prospective cohort studies. Drug Saf. 2000;22(3):169–77.CrossRefGoogle Scholar
  48. 48.
    Källén B. The problem of confounding in studies of the effect of maternal drug use on pregnancy outcome. Obstet Gynecol Int. 2012;2012:148616.CrossRefGoogle Scholar
  49. 49.
    Ehrenstein V, Sørensen HT, Bakketeig LS, Pedersen L. Medical databases in studies of drug teratogenicity: methodological issues. Clin Epidemiol. 2010;2:37–43.CrossRefGoogle Scholar
  50. 50.
    Mitchell AA. Systematic identification of drugs that cause birth defects - a new opportunity. N Engl J Med. 2003;349(26):2556–9.CrossRefGoogle Scholar
  51. 51.
    Egger M, Ebrahim S, Smith GD. Where now for meta-analysis? Int J Epidemiol. 2002;31(1):1–5.CrossRefGoogle Scholar
  52. 52.
    Chambers C. The role of teratology information services in screening for teratogenic exposures: challenges and opportunities. Am J Med Genet C Semin Med Genet. 2011;157C(3):195–200.CrossRefGoogle Scholar
  53. 53.
    Nulman I, Koren G, Rovet J, Barrera M, Streiner DL, Feldman BM. Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study. J Clin Psychiatry. 2015;76(7):e842–7.CrossRefGoogle Scholar
  54. 54.
    Bateman BT, Huybrechts KF, Fischer MA, Seely EW, Ecker JL, Oberg AS, Franklin JM, Mogun H, Hernandez-Diaz S. Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. Am J Obstet Gynecol. 2015;212(3):337.e1–14.CrossRefGoogle Scholar
  55. 55.
    Correa A, Gilboa SM, Besser LM, Botto LD, Moore CA, Hobbs CA, Cleves MA, Riehle-Colarusso TJ, Waller DK, Reece EA. Diabetes mellitus and birth defects. Am J Obstet Gynecol. 2008;199:237.e1–9.CrossRefGoogle Scholar
  56. 56.
    Källén BA. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto). 2005;45(2):44–51.CrossRefGoogle Scholar
  57. 57.
    Koren G, Madjunkova S, Maltepe C. Bias against the null hypothesis: scaring pregnant women about drugs in pregnancy. Can Fam Physician. 2014;60(5):441–2.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HE, Skaarup L, Videbech P, Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1–28.CrossRefGoogle Scholar
  59. 59.
    EMEA. Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. London: European Medicines Agency; 2008. Accessed on 12 Feb 2018.Google Scholar
  60. 60.
    Drugs and Lactation Database (LactMed). Toxnet. Bathesda, MD: National Institutes of Health; 2018. Accessed on 12 Feb 2018.Google Scholar
  61. 61.
    Hotham N, Hotham E. Drugs in breastfeeding. Aust Prescr. 2015;38:156–9.CrossRefGoogle Scholar
  62. 62.
    Hale TW. Medications and mothers’ milk. 15th ed. Amarillo, TX: Hale Publishing; 2012.Google Scholar
  63. 63.
    Ilett KF, Kristensen JH. Drug use and breastfeeding. Expert Opin Drug Saf. 2005;4:745–68.CrossRefGoogle Scholar
  64. 64.
    Madadi P, Avard D, Koren G. Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. Curr Drug Metab. 2012;13(6):721–7.CrossRefGoogle Scholar
  65. 65.
    Sistonen J, Madadi P, Ross CJ, et al. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther. 2012;91(4):692–9.CrossRefGoogle Scholar
  66. 66.
    Hale TW, Rowe HE. Medications and mothers milk. 17th ed. New York, NY: Springer Publishing Company; 2017.Google Scholar
  67. 67.
    Anderson PO, Manoguerra AS, Valdés V. A review of adverse reactions in infants from medications in breastmilk. Clin Pediatr (Phila). 2016;55(3):236–44.CrossRefGoogle Scholar
  68. 68.
    Richards JS, Williams JJ. Luteal cell receptor content for prolactin (PRL) and luteinizing hormone (LH): regulation by LH and PRL. Endocrinology. 1976;99:1571–81.CrossRefGoogle Scholar
  69. 69.
    Ito S. Chronic illness and the breastfeeding mother. J Popul Ther Clin Pharmacol. 2014;21(3):e565–8.PubMedGoogle Scholar
  70. 70.
    Kaplan YC, Koren G, Ito S, Bozzo P. Fluconazole use during breastfeeding. Can Fam Physician. 2015a;61(10):875–6.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42–52.CrossRefGoogle Scholar
  72. 72.
    Sachs HC. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132:e796–809.CrossRefGoogle Scholar
  73. 73.
    Amir LH, Pirotta MV. Medicines for breastfeeding women: a postal survey of general practitioners in Victoria. Med J Aust. 2009;191(2):126.PubMedGoogle Scholar
  74. 74.
    Holmes LB. Human teratogens: update 2010. Birth Defects Res A Clin Mol Teratol. 2011;91:1–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Yusuf Cem Kaplan
    • 1
    • 2
  • Hilal Erol-Coskun
    • 1
    • 2
  1. 1.Department of Pharmacology, Faculty of MedicineIzmir Katip Celebi UniversityIzmirTurkey
  2. 2.Teratology Information, Research and Training CenterTerafar-Izmir Katip Celebi UniversityIzmirTurkey

Personalised recommendations